Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri...

Full description

Bibliographic Details
Main Authors: Sung Hye Kim, Lorenzo Pezzoli, Harouna Yacouba, Tiekoura Coulibaly, Mamoudou H Djingarey, William A Perea, Thomas F Wierzba
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3262782?pdf=render
id doaj-5a8724906afc4791860a103b641567e1
record_format Article
spelling doaj-5a8724906afc4791860a103b641567e12020-11-25T01:46:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0171e2911610.1371/journal.pone.0029116Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.Sung Hye KimLorenzo PezzoliHarouna YacoubaTiekoura CoulibalyMamoudou H DjingareyWilliam A PereaThomas F WierzbaMenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.http://europepmc.org/articles/PMC3262782?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba
spellingShingle Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba
Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.
PLoS ONE
author_facet Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba
author_sort Sung Hye Kim
title Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.
title_short Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.
title_full Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.
title_fullStr Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.
title_full_unstemmed Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.
title_sort whom and where are we not vaccinating? coverage after the introduction of a new conjugate vaccine against group a meningococcus in niger in 2010.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.
url http://europepmc.org/articles/PMC3262782?pdf=render
work_keys_str_mv AT sunghyekim whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT lorenzopezzoli whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT harounayacouba whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT tiekouracoulibaly whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT mamoudouhdjingarey whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT williamaperea whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT thomasfwierzba whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
_version_ 1725017871428354048